SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases
Clinical trial NCT05598684 · UNKNOWN
Trial details
- NCT number
- NCT05598684
- Sponsor
- Fresenius Kabi, France
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2022-11-24
- Primary completion
- 2025-09-30
- Enrollment
- 600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.